Orchard Therapeutics reveals its plans to build-out a gene therapy manufacturing facility

An integrated commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, Orchard Therapeutics has revealed its plans to build-out a gene therapy manufacturing facility in Fremont, California.
The new 150,000-square-foot facility will significantly increase Orchard’s California footprint and adds to the Foster City and Menlo Park California sites, which oversee the ongoing development and validation of the manufacture of Orchard’s ex vivo gene therapy product candidates.
Once operational, the new site will provide significant additional CGMP manufacturing capacity for both lentiviral vector and cryopreserved cell therapy products, enhancing Orchard’s ability to manufacture and deliver gene-corrected hematopoietic stem cells for a wide range of diseases on a global basis.